Gourlay Steve 4
4 · Principia Biopharma Inc. · Filed Sep 20, 2018
Insider Transaction Report
Form 4
Gourlay Steve
Chief Medical Officer
Transactions
- Conversion
Series B-3 Preferred Stock
2018-09-18−7,269→ 0 total→ Common Stock (7,269 underlying) - Conversion
Common Stock
2018-09-18+7,269→ 107,857 total
Holdings
- 625
Warrant (Right to Buy)
Exp: 2022-12-29→ Common Stock (625 underlying)
Footnotes (3)
- [F1]Each share of Preferred Stock automatically converted into one (1) share of Common Stock, for no additional consideration, upon the consummation of the Issuer's initial public offering.
- [F2]This warrant has converted from a warrant to purchase Series B-3 Preferred Stock into a warrant to purchase Common Stock.
- [F3]This warrant is exercisable at any time.